Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer

Harbour BioMed, a global biopharmaceutical company, has appointed Dr. Jenny Xie as its Chief Scientific Officer, Immunology and Head of Global External Innovation, where she will lead Harbour BioMed’s global external innovation strategy in immunology, managing ongoing strategic collaborations with key partners, as well as identifying and pursuing new partnership opportunities. Additionally, she will oversee all activities at the company’s Harbour BioMed-AstraZeneca Innovation Lab in Beijing.

Xie will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed.

“We are very pleased to welcome Dr. Jenny Xie to our executive team,” remarked Wang. “Her extensive experience in drug discovery and development in immunology will be invaluable as we work to strengthen our R&D capabilities and drive innovation across our pipeline. I am confident her leadership will significantly advance our immunology research and global collaboration efforts.”

Experience

Xie brings more than 25 years of experience in the biopharmaceutical industry. Prior to joining Harbour BioMed, she served as Executive Director and Head of Discovery Immunology at Bristol Myers Squibb, where she led research efforts in autoimmune diseases and contributed to the discovery, evaluation, and clinical translation of novel therapeutic approaches. Prior to that, she also held scientific leadership roles at Merck, building extensive experience in early-stage research and development.

Xie received her Ph.D. in Immunology from Boston University School of Medicine and her bachelor’s degree in Biology from Fudan University.

“I am truly excited to join an incredible company like Harbour BioMed and look forward to working with everyone toward our shared goal of transforming patients’ lives through innovation, speed, and global collaboration,” she said.